— AMAG Pharmaceuticals (NASDAQ: AMAG) reported a net loss of $199.9 million or $5.89 per share for the fourth quarter of 2019 vs. $0.36 per share loss expected.
— During the fourth quarter, the company recorded impairment charges of $155 million.
— Revenue increased to $89.7 million from $88.1 million last year vs. $88.39 million expected.
— For fiscal 2020, AMAG expects revenue to be between $230 million and $280 million. Non-GAAP adjusted EBITDA is expected to be in the range of $20 million to $50 million.
— 2020 key priorities include completing CEO transition, divest Intrarosa and Vyleesi, drive continued Feraheme growth and work with the FDA to maintain patient access to Makena.
— AMAG also announced today that its Chief Medical Officer Julie Krop will be leaving the company with effect from March 31, 2020. The Board has initiated the search for a permanent CMO.
— AMAG stock had retreated 24% in the past three months and 45% from this time last year.
General Mills Inc. (NYSE: GIS) reported fourth quarter 2022 earnings results today. Net sales increased 8% year-over-year to $4.9 billion. Organic net sales rose 13%. Net earnings attributable to General
Shares of KB Home (NYSE: KBH) have dropped 35% year-to-date and 28% over the past 12 months. Last week, the company reported second quarter 2022 earnings results that surpassed expectations
Trade Desk, Inc. (NASDAQ: TTD) has remained a much sought-after demand-side platform despite challenging market conditions and growing inflationary pressure, but its stock suffered heavy selling in recent months. The